Patient Research
Sign in
All studies
AuthorisedHuman Pharmacology (Phase I)- Bioequivalence StudyInterventional

Randomised, crossover bioequivalence clinical trial of edoxaban 60 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

At a glance

Status
Authorised
Phase
Human Pharmacology (Phase I)- Bioequivalence Study
Sponsor
Biohorm S.L.
Enrolment target
15
Start
22 Dec 2022
Edoxaban is used as antithrombotic agentsbut it is a bioequivalence trial and the study population is healthy volunteers

Who may be eligible?

Age 18 Years to any · Sex: All

Locations (1)

  • —
    Spain

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.